SPRAVATO™ is only available at Risk Evaluation and Mitigation Strategy (REMS) certified facilities. Lenox Hill Mind Care is REMS certified. The medical staff have been trained to prescribe, dispense and administer SPRAVATO™ and have established processes and procedures in accordance with the REMS.
We have been focused on treating TRD (treatment-resistant depression) patients since we were founded in 2009 and providing the most innovative patient-centric care to give our patients the best chance for recovery.
Spravato or Esketamine is FDA-Approved and a prescription nasal spray for use in conjunction with an oral antidepressant in adults with depression who have not responded adequately to antidepressants.
Our Process:
1. Intake and Preparation
We offer Spravato treatment to patients who qualify under their insurance plan and in accordance with FDA’s safety requirements.
Most insurance companies require at least two prior antidepressant trials, and for patients to be taking an oral antidepressant during the course of Spravato treatment.
2. In-Person Consultation
Visit our clinic for your in-person consultation. During this 50-minute session, you and our clinician will discuss your history, current symptoms, and treatment options, including Spravato.
After scheduling your first dosing session, you’ll tour the facility and meet other Lenox Hill Mind Care staff.
3. Personalized Treatment
Spravato appointments are typically scheduled twice weekly for the first month, and once weekly for the second month.
You will self-administer the nasal spray under the supervision of your prescriber. Each session lasts about two hours.
The Science Behind Spravato
Spravato targets the glutamate system in the brain, which plays an important role in healthy brain functioning.
Glutamate is a highly abundant neurotransmitter, responsible for facilitating signals between nerve cells.
Although Spravato’s exact mechanism of action is not yet known, it’s thought to create new connections in the brain, allowing for behavioral and cognitive changes to occur more readily and rapidly in patients with treatment-resistant depression. Clinical trials have shown a 69% response rate and 52% remission rate in patients treated with Spravato.
We launched in Scarsdale in November and anticipate in New York, early 2022.